Infectious complications of vascular anomalies treated with sirolimus: A systematic review

Keyphrases

• Sirolimus 100%
• Infectious Complications 100%
• Vascular Anomalies 100%
• Pneumocystis Jirovecii 50%
• Fatality 33%
• MTOR Inhibitor 33%
• Infection Risk 16%
• Pneumonia 16%
• Viral 16%
• Immunosuppressive Agents 16%
• Infection Prevention 16%
• Well-defined 16%
• Age of Infection 16%
• Common Terminology Criteria for Adverse Events (CTCAE) 16%
• Mammalian Target of Rapamycin Inhibition 16%
• Upper Respiratory Tract 16%
• Bacteremia 16%
• Everolimus 16%
• Cutaneous Infection 16%
• Vascular Malformation 16%
• Infection-related 16%
• Viral Respiratory Infections 16%
• Vascular Tumor 16%
• Total Infections 16%
• Non-severe 16%
• PRISMA Guidelines 16%
• Kaposiform Hemangioendothelioma 16%

Medicine and Dentistry

• Systematic Review 100%
• Infectious Complication 100%
• Vascular Anomaly 100%
• Rapamycin 100%
• Infection 66%
• Pneumocystis Jirovecii 50%
• Mammalian Target of Rapamycin Inhibitor 33%
• Fatality 33%
• Adverse Event 16%
• Immunosuppressive Drug 16%
• Carbetimer 16%
• Infection Prevention 16%
• Skin Infection 16%
• Vascular Tissue Neoplasm 16%
• Mechanistic Target of Rapamycin 16%
• Bloodstream Infection 16%
• Hemangioendothelioma 16%
• Viral Respiratory Tract Infection 16%
• Everolimus 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Rapamycin 100%
• Infectious Complication 100%
• Congenital Blood Vessel Malformation 100%
• Infection 83%
• Pneumocystis Jiroveci 50%
• Mammalian Target of Rapamycin Inhibitor 33%
• Fatality 33%
• Adverse Event 16%
• Immunosuppressive Agent 16%
• Carbetimer 16%
• Bloodstream Infection 16%
• Vascular Tumor 16%
• Mammalian Target of Rapamycin 16%
• Viral Respiratory Tract Infection 16%
• Everolimus 16%
• Skin Infection 16%
• Hemangioendothelioma 16%